Recent advancements in liposome technology

Filipczak, Nina; Pan, Jiayi; Yalamarty, Satya Siva Kishan; Torchilin, Vladimir P.

doi:10.1016/j.addr.2020.06.022

Cited by 396 publications

(208 citation statements)

References 185 publications

Supporting

Mentioning

200

Contrasting

Unclassified

Order By: Relevance

“…Alternatively, LNDFpi was made by adding FA-PEG-DSPC to preformed DSPC/Chol/mPEG-DSPE liposomes containing ND using the post-insertion method ( Figure 6D). The researchers were able to demonstrate specificity within their drug delivery platform, observing approximately 100 nmol/mg cell protein in P-gp/FAR positive cell lines (MDA-231 and TUBO) as opposed to 50 nmol/mg cell protein in the P-gp/FAR negative cell line MCF-7 ( Figure 6D) after 72 h. Within a mouse TUBO-cell xenograft model, the researchers also observed that treatment with the LNDF liposomes resulted in a tumor volume of 1200 mm 3 over 21 days, while mice treated with LND (without folic acid) experienced an average tumor volume of 3000 mm 3 . Mice treated with non-liposomal ND had tumors with an average volume of 4000 mm 3 ( Figure 6D).…”

Section: Other Small Molecule-liposome Bioconjugatesmentioning

confidence: 87%

“…This is due in a large part to: 1-their facile fabrication methods, 2-their ability to encapsulate a wide variety of drugs and molecules (regardless of hydrophobicity, charge, size, and other physicochemical properties), and 3-their biocompatibility. Since the FDA approval of Doxil ® (a liposomal formulation of the anticancer drug, doxorubicin) in 1995 [2], more than a dozen liposomal drug delivery systems have been approved for clinical use with many more currently in the pipeline (see Section 5) [3][4][5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

et al. 2020

View full text Add to dashboard Cite

In nanoparticle (NP)-mediated drug delivery, liposomes are the most widely used drug carrier, and the only NP system currently approved by the FDA for clinical use, owing to their advantageous physicochemical properties and excellent biocompatibility. Recent advances in liposome technology have been focused on bioconjugation strategies to improve drug loading, targeting, and overall efficacy. In this review, we highlight recent literature reports (covering the last five years) focused on bioconjugation strategies for the enhancement of liposome-mediated drug delivery. These advances encompass the improvement of drug loading/incorporation and the specific targeting of liposomes to the site of interest/drug action. We conclude with a section highlighting the role of bioconjugation strategies in liposome systems currently being evaluated for clinical use and a forward-looking discussion of the field of liposomal drug delivery.

show abstract

Section: Other Small Molecule-liposome Bioconjugatesmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Liposomes are small spherical vesicles and normally possess a closed lipid bilayer resembling a cell membrane and an aqueous inner chamber, which could encapsulate hydrophilic and hydrophobic molecules, respectively. As multifunctional drug-carriers, liposomes have the advantages of biocompatibility, stability, membrane fusion, gene transfection, controlled release, and entrapment protection, widely applied in pharmaceutical, cosmetics, and food fields [107]. There is a diversity of liposome structures including single or multiple lipid bilayers, and one or more compartments.…”

Section: Liposomesmentioning

confidence: 99%

Contributions of Glycolipid Biosurfactants and Glycolipid-Modified Materials to Antimicrobial Strategy: A Review

et al. 2021

View full text Add to dashboard Cite

Glycolipid biosurfactants are natural amphiphiles and have gained particular interest recently in their biodegradability, diversity, and bioactivity. Microbial infection has caused severe morbidity and mortality and threatened public health security worldwide. Glycolipids have played an important role in combating many diseases as therapeutic agents depending on the self-assembly property, the anticancer and anti-inflammatory properties, and the antimicrobial properties, including antibacterial, antifungal, and antiviral effects. Besides, their role has been highlighted as scavengers in impeding the biofilm formation and rupturing mature biofilm, indicating their utility as suitable anti-adhesive coating agents for medical insertional materials leading to a reduction in vast hospital infections. Notably, glycolipids have been widely applied to the synthesis of novel antimicrobial materials due to their excellent amphipathicity, such as nanoparticles and liposomes. Accordingly, this review will provide various antimicrobial applications of glycolipids as functional ingredients in medical therapy.

show abstract

“…The use of liposomes as a drug delivery system offers numerous advantages such as: high biodegradability and biocompatibility with low toxicity, ability of self-assembly, possibility of simple removal from the body and increased efficacy and bioavailability of encapsulated compounds [ 10 , 11 ]. Most importantly, this type of nanocarrier can ensure encapsulation of both hydrophobic and hydrophilic agents, in the phospholipid bilayer and aqueous core, respectively [ 12 , 13 ]. These vesicular nanostructures also provide the ability to modify key physicochemical properties, i.e., size and surface, which is crucial in the subsequent application [ 14 ].…”

Section: Introductionmentioning

confidence: 99%

Novel Surface-Modified Bilosomes as Functional and Biocompatible Nanocarriers of Hybrid Compounds

Waglewska¹,

Pucek-Kaczmarek²,

Bazylińska³

2020

Nanomaterials

View full text Add to dashboard Cite

In the present contribution, we demonstrate a new approach for functionalization of colloidal nanomaterial consisting of phosphatidylcholine/cholesterol-based vesicular systems modified by FDA-approved biocompatible components, i.e., sodium cholate hydrate acting as a biosurfactant and Pluronic P123—a symmetric triblock copolymer comprising poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) blocks Eight novel bilosome formulations were prepared using the thin-film hydration method followed by sonication and extrusion in combination with homogenization technique. The optimization studies involving the influence of the preparation technique on the nanocarrier size (dynamic light scattering), charge (electrophoretic light scattering), morphology (transmission electron microscopy) and kinetic stability (backscattering profiles) revealed the most promising candidate for the co-loading of model active compounds of various solubility; namely, hydrophilic methylene blue and hydrophobic curcumin. The studies of the hybrid cargo encapsulation efficiency (UV-Vis spectroscopy) exhibited significant potential of the formulated bilosomes in further biomedical and pharmaceutical applications, including drug delivery, anticancer treatment or diagnostics.

show abstract

Recent advancements in liposome technology

Cited by 396 publications

References 185 publications

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

Contributions of Glycolipid Biosurfactants and Glycolipid-Modified Materials to Antimicrobial Strategy: A Review

Novel Surface-Modified Bilosomes as Functional and Biocompatible Nanocarriers of Hybrid Compounds

Contact Info

Product

Resources

About